Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AtriCure, Inc. - Common Stock
(NQ:
ATRC
)
61.28
-4.25 (-6.49%)
Delayed Quote
Updated: 4:00 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AtriCure, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
AtriCure (ATRC) Q3 2026 Earnings Call Transcript
↗
November 04, 2026
Net income turned positive as profitability outlook was raised for the year.
Via
The Motley Fool
Topics
Earnings
What AtriCure (ATRC) Said on Its Q3 Earnings Call
↗
November 03, 2026
AtriCure (NASDAQ:ATRC) reported third-quarter 2026 revenue of $154.5 million, up 15% from a year earlier, as growth in its U.S. open ablation, appendage management and pain management businesses helped...
Via
MarketBeat
Topics
Earnings
AtriCure (NASDAQ:ATRC) Q3 2026 Earnings: EPS Beat, Revenue Inline, Soft Guidance Weighs on Shares
↗
November 03, 2026
Via
Chartmill
AtriCure Reports Third Quarter 2026 Financial Results
November 03, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure (NASDAQ:ATRC) Combines Technical Strength With a Breakout Setup
↗
October 24, 2026
Via
Chartmill
AtriCure (NASDAQ:ATRC) Profitability Surge Drives After-Hours Rally Despite Inline Revenue
↗
July 23, 2026
Via
Chartmill
AtriCure (NASDAQ:ATRC) Q1 Results Beat Estimates as Company Reaches Key Profitability Milestone
↗
May 05, 2026
Via
Chartmill
AtriCure to Participate at Upcoming Investor Conferences
October 26, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Announce Third Quarter 2026 Financial Results
October 13, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure CTO Sells 3,657 Shares
↗
September 12, 2026
Privitera executed the sale under a pre-established Rule 10b5-1 trading plan.
Via
The Motley Fool
Topics
Regulatory Compliance
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
August 25, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
↗
August 11, 2026
AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product...
Via
MarketBeat
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
↗
August 07, 2026
The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.
Via
The Motley Fool
Topics
Regulatory Compliance
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
↗
August 07, 2026
Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.
Via
The Motley Fool
Topics
Regulatory Compliance
AtriCure to Participate at Upcoming Investor Conferences
July 27, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure Q2 Earnings Call Highlights
↗
July 23, 2026
AtriCure (NASDAQ:ATRC) reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management,...
Via
MarketBeat
Topics
Earnings
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript
↗
July 23, 2026
AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you...
Via
Benzinga
Topics
Earnings
AtriCure Reports Second Quarter 2026 Financial Results
July 23, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Announce Second Quarter 2026 Financial Results
July 02, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
May 27, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
↗
May 12, 2026
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding...
Via
MarketBeat
AtriCure (ATRC) Q1 2026 Earnings Transcript
↗
May 06, 2026
AtriCure (ATRC) Q1 2026 Earnings Transcript
Via
The Motley Fool
AtriCure Reports First Quarter 2026 Financial Results
May 05, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
April 28, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Announce First Quarter 2026 Financial Results
April 14, 2026
From
AtriCure, Inc.
Via
Business Wire
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
↗
March 21, 2026
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
↗
March 21, 2026
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
↗
March 21, 2026
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
Via
The Motley Fool
Topics
Regulatory Compliance
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
↗
March 21, 2026
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...
Via
The Motley Fool
Topics
Derivatives
ETFs
Regulatory Compliance
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
↗
March 18, 2026
This medical device innovator for cardiac surgery reported a notable insider sale amid a year of negative total returns.
Via
The Motley Fool
Topics
Derivatives
Regulatory Compliance
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
